Precision Medicine Still Runs on Unforgiving Proof Thresholds
Biotech investors often reserve their emotional energy for glamorous failures: breakthrough drugs that miss endpoints, gene-editing platforms that stumble, cell…
Author: Jane Aubrey
Jane Aubrey brings over a decade of experience as a clinical researcher to her reporting on drug development and regulatory pathways. At The Biotech Codex, she breaks down complex trial data and analyzes the pipeline strategies of both emerging biotechs and legacy pharma giants. Her coverage demystifies the arduous journey from bench to bedside, keeping industry professionals informed on the latest therapeutic breakthroughs.
TREGZI Turns the Transplant Itself Into the Therapy
Orca Bio’s newly approved TREGZI matters because it points to a different kind of innovation. Instead of treating transplant complications…
Gene Editing Is Moving Into Childhood, and the System Is Not Ready
The most important feature of a curative therapy is not always its mechanism. Sometimes it is the age at which…
Precision Oncology Is Becoming a Diagnostics Discipline
A good deal of biotech storytelling still assumes that the decisive event is the drug itself: the molecule works, the…
The FDA Is Moving Upstream Into Factory Formation
For decades, the drug industry treated regulation and manufacturing as sequential problems. Companies developed an asset, built or secured production…
Biotech Buyers Are Paying for Cash-Flow Bridges, Not Just Science
The most revealing biotech deal of the past two days is not really a science-acquisition story at all. It is…
Biopharma Is Paying for Assets That Rewire the Standard of Care
The most interesting biotech deal of the day is not important because of its size alone. It is important because…
Life-Science Tools Are Being Valued Like Therapeutic Platforms
Biotech’s most revealing deal this week did not center on a drug asset, a phase 3 readout, or a late-stage…
Biotech Corridors Are Becoming Products of Their Own
Biotech hubs used to sell themselves with a familiar formula: good universities, venture capital, hospital systems, and a deep pool…
Rare Outbreaks Are Becoming Real-Time Clinical Platforms
One of the more consequential healthcare developments of the past two days has arrived far from the usual biotech spotlight.…
Clinical-Trial Speed Is Becoming a National Biotech Asset
Biotech policy has spent the last several years talking as if national competitiveness were mainly a question of patents, subsidies,…